Bristol's Opdivo boosts kidney cancer survival beyond two years
September 25, 2015 at 18:00 PM EDT
Sept 26 (Reuters) - Bristol-Myers Squibb's immunotherapy drug Opdivo extended kidney cancer survival rates by more than two years in a late-stage trial, setting it up to be used beyond melanoma and lung cancer.
